It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Antenatal inflammation as seen with chorioamnionitis is harmful to foetal/neonatal organ development including to eyes. Although the major pro-inflammatory cytokine IL-1β participates in retinopathy induced by hyperoxia (a predisposing factor to retinopathy of prematurity), the specific role of antenatal IL-1β associated with preterm birth (PTB) in retinal vasculopathy (independent of hyperoxia) is unknown. Using a murine model of PTB induced with IL-1β injection in utero, we studied consequent retinal and choroidal vascular development; in this process we evaluated the efficacy of IL-1R antagonists. Eyes of foetuses exposed only to IL-1β displayed high levels of pro-inflammatory genes, and a persistent postnatal infiltration of inflammatory cells. This prolonged inflammatory response was associated with: (1) a marked delay in retinal vessel growth; (2) long-lasting thinning of the choroid; and (3) long-term morphological and functional alterations of the retina. Antenatal administration of IL-1R antagonists – 101.10 (a modulator of IL-1R) more so than Kineret (competitive IL-1R antagonist) – prevented all deleterious effects of inflammation. This study unveils a key role for IL-1β, a major mediator of chorioamnionitis, in causing sustained ocular inflammation and perinatal vascular eye injury, and highlights the efficacy of antenatal 101.10 to suppress deleterious inflammation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Ophthalmology and Pharmacology, CHU Sainte-Justine Research Centre, Departments of Pediatrics, Montréal, Canada
2 Ophthalmology and Pharmacology, CHU Sainte-Justine Research Centre, Departments of Pediatrics, Montréal, Canada; Université de Montréal, Department of Pharmacology, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
3 Ophthalmology and Pharmacology, CHU Sainte-Justine Research Centre, Departments of Pediatrics, Montréal, Canada (GRID:grid.14848.31)
4 Ophthalmology and Pharmacology, CHU Sainte-Justine Research Centre, Departments of Pediatrics, Montréal, Canada (GRID:grid.14848.31); McGill University, Department of Pharmacology and Therapeutics, Montréal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
5 Ophthalmology and Pharmacology, CHU Sainte-Justine Research Centre, Departments of Pediatrics, Montréal, Canada (GRID:grid.14709.3b)
6 Ophthalmology and Pharmacology, CHU Sainte-Justine Research Centre, Departments of Pediatrics, Montréal, Canada (GRID:grid.14709.3b); McGill University, Department of Pharmacology and Therapeutics, Montréal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
7 University of Adelaide, Department of Obstetrics and Gynaecology, Adelaide, Australia (GRID:grid.1010.0) (ISNI:0000 0004 1936 7304)
8 University of Western Australia King Edward Memorial Hospital, Div Obstetrics & Gynaecology, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910)
9 University of Washington, Department of Obstetrics & Gynaecology, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
10 Pediatrics and Physiology, University of Alberta, Departments of Obstetrics and Gynaecology, Edmonton, Canada (GRID:grid.17089.37)
11 Maisonneuve-Rosemont Hospital Research Centre, Department of Ophthalmology, Montréal, Canada (GRID:grid.414216.4) (ISNI:0000 0001 0742 1666)
12 Université de Montréal, Department of Chemistry, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
13 Ophthalmology and Pharmacology, CHU Sainte-Justine Research Centre, Departments of Pediatrics, Montréal, Canada (GRID:grid.14848.31); Université de Montréal, Department of Pharmacology, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); McGill University, Department of Pharmacology and Therapeutics, Montréal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
14 Université de Montréal, School of Optometry, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)